Missing the target in cancer therapy comment

被引：26

作者：

Adashek, Jacob J. ^{[1
]}

Goloubev, Alexey ^{[2
]}

Kato, Shumei ^{[3
,4
]}

Kurzrock, Razelle ^{[3
,4
]}

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33620 USA

[2] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA

[3] Univ Calif San Diego, Ctr Personalized Canc Therapy, Moores Canc Ctr, La Jolla, CA 92093 USA

[4] Univ Calif San Diego, Dept Med, Div Hematol & Oncol, Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

NATURE CANCER | 2021年 / 2卷 / 04期

关键词：

CELL LUNG-CANCER; COMBINATION; BENEFIT; TRIAL;

D O I：

10.1038/s43018-021-00204-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or immune-targeted cancer therapies improves the outcome of individual patients and increases the chances of successful drug approval. However, for many lethal malignancies, the majority of clinical trials are conducted with patients who do not have biomarkers and hence they miss the target.

引用

页码：369 / 371

页数：3

共 16 条

[1] From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm [J].

Adashek, Jacob J. ;

Subbiah, Vivek ;

Kurzrock, Razelle .

TRENDS IN CANCER, 2021, 7 (01) :15-28

[2] Next Generation Sequencing in metastatic castrate-resistant prostate cancer [J].

Adashek, Jacob J. ;

Salgia, Meghan ;

Pal, Sumanta K. .

UROLOGY CASE REPORTS, 2018, 19 :60-62

[3]

[Anonymous], 2018, J CLIN ONCOL

[4] Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses [J].

Blumenthal, Gideon M. ;

Karuri, Stella W. ;

Zhang, Hui ;

Zhang, Lijun ;

Khozin, Sean ;

Kazandjian, Dickran ;

Tang, Shenghui ;

Sridhara, Rajeshwari ;

Keegan, Patricia ;

Pazdur, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :1008-+

[5] Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval [J].

Fontes Jardim, Denis L. ;

Schwaederle, Maria ;

Wei, Caimiao ;

Lee, J. Jack ;

Hong, David S. ;

Eggermont, Alexander M. ;

Schilsky, Richard L. ;

Mendelsohn, John ;

Lazar, Vladimir ;

Kurzrock, Razelle .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11)

[6] Randomized Clinical Trials in Pancreatic Cancer [J].

Goel, Neha ;

Reddy, Sanjay S. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 26 (04) :767-790

[7] Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer [J].

Golan, Talia ;

Hammel, Pascal ;

Reni, Michele ;

Van Cutsem, Eric ;

Macarulla, Teresa ;

Hall, Michael J. ;

Park, Joon-Oh ;

Hochhauser, Daniel ;

Arnold, Dirk ;

Oh, Do-Youn ;

Reinacher-Schick, Anke ;

Tortora, Giampaolo ;

Alguel, Hana ;

O'Reilly, Eileen M. ;

McGuinness, David ;

Cui, Karen Y. ;

Schlienger, Katia ;

Locker, Gershon Y. ;

Kindler, Hedy L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :317-327

[8] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

[9] Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2 [J].

Herbst, RS ;

Giaccone, G ;

Schiller, JH ;

Natale, RB ;

Miller, V .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :785-794

[10] Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review [J].

Jardim, Denis L. ;

Groves, Eric S. ;

Breitfeld, Philip P. ;

Kurzrock, Razelle .

CANCER TREATMENT REVIEWS, 2017, 52 :12-21

← 1 2 →